Shares of C.R. Bard Inc. (NYSE:BCR) have earned an average recommendation of “Hold” from the seventeen analysts that are covering the stock. Nine analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $233.07.

BCR has been the topic of a number of research reports. Wells Fargo & Co. upgraded C.R. Bard from a “market perform” rating to an “outperform” rating in a research note on Friday, September 16th. Barclays PLC upped their price objective on C.R. Bard from $224.00 to $235.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 27th. Leerink Swann reaffirmed a “market perform” rating and set a $233.00 price objective (down previously from $240.00) on shares of C.R. Bard in a research report on Thursday, July 28th. Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Thursday, August 4th. Finally, Morgan Stanley reaffirmed a “hold” rating and set a $240.00 price objective on shares of C.R. Bard in a research report on Thursday, July 28th.

Shares of C.R. Bard (NYSE:BCR) opened at 203.77 on Thursday. C.R. Bard has a 12 month low of $172.21 and a 12 month high of $239.43. The firm’s 50-day moving average price is $220.29 and its 200-day moving average price is $222.50. The firm has a market cap of $14.98 billion, a PE ratio of 30.78 and a beta of 0.67.

C.R. Bard (NYSE:BCR) last released its quarterly earnings results on Tuesday, October 25th. The company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.55 by $0.09. C.R. Bard had a return on equity of 48.13% and a net margin of 14.05%. The company had revenue of $941.90 million for the quarter, compared to analysts’ expectations of $931.66 million. During the same period in the prior year, the firm earned $2.28 earnings per share. The firm’s revenue was up 8.8% compared to the same quarter last year. Analysts expect that C.R. Bard will post $10.26 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, November 4th. Stockholders of record on Monday, October 24th were paid a dividend of $0.26 per share. The ex-dividend date of this dividend was Thursday, October 20th. This represents a $1.04 annualized dividend and a dividend yield of 0.51%. C.R. Bard’s dividend payout ratio (DPR) is 15.48%.

In other news, VP Betty D. Larson sold 4,032 shares of the stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $225.33, for a total transaction of $908,530.56. Following the completion of the sale, the vice president now owns 10,298 shares in the company, valued at $2,320,448.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP John A. Deford sold 7,928 shares of the stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $221.06, for a total transaction of $1,752,563.68. The disclosure for this sale can be found here. Insiders own 0.97% of the company’s stock.

Large investors have recently made changes to their positions in the company. Cypress Capital Group increased its stake in shares of C.R. Bard by 0.3% in the first quarter. Cypress Capital Group now owns 2,392 shares of the company’s stock worth $485,000 after buying an additional 7 shares during the last quarter. Smithfield Trust Co. increased its stake in shares of C.R. Bard by 0.6% in the third quarter. Smithfield Trust Co. now owns 1,116 shares of the company’s stock worth $251,000 after buying an additional 7 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its stake in shares of C.R. Bard by 0.4% in the third quarter. Municipal Employees Retirement System of Michigan now owns 2,320 shares of the company’s stock worth $520,000 after buying an additional 10 shares during the last quarter. Foster & Motley Inc. increased its stake in shares of C.R. Bard by 0.3% in the second quarter. Foster & Motley Inc. now owns 3,851 shares of the company’s stock worth $906,000 after buying an additional 11 shares during the last quarter. Finally, Cleararc Capital Inc. increased its stake in shares of C.R. Bard by 0.9% in the second quarter. Cleararc Capital Inc. now owns 1,795 shares of the company’s stock worth $422,000 after buying an additional 16 shares during the last quarter. Institutional investors and hedge funds own 88.17% of the company’s stock.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.

5 Day Chart for NYSE:BCR

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.